What is LIMN's health score?

Liminatus Pharma, Inc. (LIMN) has a TradeApes health score of 48 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is LIMN's estimated fair value?

Based on our 5-year discounted cash flow model, Liminatus Pharma, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is LIMN undervalued or overvalued?

Our model currently rates LIMN as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for LIMN... Refresh in a moment for the full analysis.

Liminatus Pharma, Inc. (LIMN)

Healthcare Inconclusive inconclusive mixed

$0.14

Updated: 2026-06-06

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

50 Mixed

Relative Value

40 Weak

Capital Allocation

40 Weak

Risk

65 Healthy

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.